Cryoport Systems Honored with Simon Ellison Supply Chain Innovation Award at Advanced Therapies Awards 2025
Celebrating Leadership in Integrative, Temperature-Controlled Supply Chain Solutions for Advanced Therapies
Cryoport Systems is proud to announce that we were awarded the prestigious Simon Ellison Supply Chain Innovation Award last night at Advanced Therapies Awards 2025. This accolade recognizes organizations that have made exceptional contributions to advancing supply chain management, with a focus on its critical role in improving patient outcomes.
This award reflects Cryoport Systems’ unwavering commitment to Enabling the Outcome™ for cell and gene therapy developers through cutting-edge, temperature-controlled supply chain solutions. With decades of experience and a robust platform of integrated logistics, cryopreservation, BioServices and biostorage, and regulatory support through our consulting solutions, we empower life sciences organizations to deliver their therapies safely and reliably to patients worldwide.
“Our mission is to ensure that life-saving therapies are carefully managed at every stage, preserving their integrity and meeting the needs of patients who depend on them,” said Aruna Mor, Chief Commercial Officer. “Receiving the Simon Ellison Supply Chain Innovation Award is a tremendous honor and underscores the hard work of our dedicated teams, as well as our collaborations with partners across the industry.”
This recognition comes on the heels of Cryoport Systems’ innovative developments in the supply chain landscape, including the Cryoport Elite™ ultra-cold shipping system. This industry-leading solution, developed in collaboration with biopharmaceutical partners, addresses critical gaps in transporting temperature-sensitive therapies by providing unprecedented reliability, performance, and compliance.
In letters of support submitted on behalf of Cryoport Systems, the company’s clients commended the company’s “operational excellence” and “forward-thinking approach,” noting its role in “safeguarding the viability and quality” of advanced therapies. One of their clients highlighted how Cryoport Systems’ solutions have “streamlined processes that directly contribute to improving patient outcomes.”
As an organization founded on a passion for innovation, Cryoport Systems remains steadfast in its dedication to advancing supply chain management for the life sciences. This recognition serves as a testament to our ongoing efforts to support groundbreaking therapies and improve the lives of patients globally.
We are deeply honored to receive the Simon Ellison Supply Chain Innovation Award and extend our heartfelt gratitude to the Advanced Therapies Awards committee and our industry partners who continually inspire us. This award is a testament to the trust our clients place in us and the collaborative spirit that drives innovation across the advanced therapies space.